Literature DB >> 23811283

Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection.

Min-Chul Kim1, Jong-Seok Lee, Young-Man Kwon, Eunju O, Youn-Jeong Lee, Jun-Gu Choi, Bao-Zhong Wang, Richard W Compans, Sang-Moo Kang.   

Abstract

The influenza M2 ectodomain (M2e) is poorly immunogenic and has some amino acid changes among isolates from different host species. We expressed a tandem repeat construct of heterologous M2e sequences (M2e5x) derived from human, swine, and avian origin influenza A viruses on virus-like particles (M2e5x VLPs) in a membrane-anchored form. Immunization of mice with M2e5x VLPs induced protective antibodies cross-reactive to antigenically different influenza A viruses and conferred cross protection. Anti-M2e antibodies induced by heterologous M2e5x VLPs showed a wider range of cross reactivity to influenza A viruses at higher levels than those by live virus infection, homologous M2e VLPs, or M2e monoclonal antibody 14C2. Fc receptors were found to be important for mediating protection by immune sera from M2e5x VLP vaccination. The present study provides evidence that heterologous recombinant M2e5x VLPs can be more effective in inducing protective M2e immunity than natural virus infection and further supports an approach for developing an effective universal influenza vaccine.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cross protection; M2e VLPs; M2e cross-reactivity

Mesh:

Substances:

Year:  2013        PMID: 23811283      PMCID: PMC3788098          DOI: 10.1016/j.antiviral.2013.06.010

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  40 in total

1.  Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design.

Authors:  Juliana Bessa; Nicole Schmitz; Heather J Hinton; Katrin Schwarz; Andrea Jegerlehner; Martin F Bachmann
Journal:  Eur J Immunol       Date:  2008-01       Impact factor: 5.532

Review 2.  Update on avian influenza A (H5N1) virus infection in humans.

Authors:  Abdel-Nasser Abdel-Ghafar; Tawee Chotpitayasunondh; Zhancheng Gao; Frederick G Hayden; Duc Hien Nguyen; Menno D de Jong; Azim Naghdaliyev; J S Malik Peiris; Nahoko Shindo; Santoso Soeroso; Timothy M Uyeki
Journal:  N Engl J Med       Date:  2008-01-17       Impact factor: 91.245

3.  Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys.

Authors:  Tong-Ming Fu; Karen M Grimm; Michael P Citron; Daniel C Freed; Jiang Fan; Paul M Keller; John W Shiver; Xiaoping Liang; Joseph G Joyce
Journal:  Vaccine       Date:  2009-01-13       Impact factor: 3.641

4.  Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus.

Authors:  Paul P Heinen; Frans A Rijsewijk; Els A de Boer-Luijtze; André T J Bianchi
Journal:  J Gen Virol       Date:  2002-08       Impact factor: 3.891

5.  Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus.

Authors:  Min-Chul Kim; Jae-Min Song; Eunju O; Young-Man Kwon; Youn-Jeong Lee; Richard W Compans; Sang-Moo Kang
Journal:  Mol Ther       Date:  2012-12-18       Impact factor: 11.454

6.  Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity.

Authors:  Andrea Jegerlehner; Nicole Schmitz; Tazio Storni; Martin F Bachmann
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

7.  Induction of heterosubtypic immunity to influenza virus by intranasal immunization.

Authors:  Fu-Shi Quan; Richard W Compans; Huan H Nguyen; Sang-Moo Kang
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

8.  CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.

Authors:  Dubravka Grdic Eliasson; Karim El Bakkouri; Karin Schön; Anna Ramne; Els Festjens; Björn Löwenadler; Walter Fiers; Xavier Saelens; Nils Lycke
Journal:  Vaccine       Date:  2008-01-10       Impact factor: 3.641

9.  An influenza A vaccine based on tetrameric ectodomain of matrix protein 2.

Authors:  Marina De Filette; Wouter Martens; Kenny Roose; Tom Deroo; Frederik Vervalle; Mostafa Bentahir; Joel Vandekerckhove; Walter Fiers; Xavier Saelens
Journal:  J Biol Chem       Date:  2008-02-05       Impact factor: 5.157

10.  Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1.

Authors:  Stephen Mark Tompkins; Zi-Shan Zhao; Chia-Yun Lo; Julia A Misplon; Teresa Liu; Zhiping Ye; Robert J Hogan; Zhengqi Wu; Kimberly A Benton; Terrence M Tumpey; Suzanne L Epstein
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883

View more
  39 in total

1.  A dual purpose universal influenza vaccine candidate confers protective immunity against anthrax.

Authors:  Maria T Arévalo; Junwei Li; Diana Diaz-Arévalo; Yanping Chen; Ashley Navarro; Lihong Wu; Yongyong Yan; Mingtao Zeng
Journal:  Immunology       Date:  2016-12-05       Impact factor: 7.397

2.  Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection.

Authors:  Min-Chul Kim; Yu-Na Lee; Eun-Ju Ko; Jong Seok Lee; Young-Man Kwon; Hye Suk Hwang; Jae-Min Song; Byung-Min Song; Youn-Jeong Lee; Jun-Gu Choi; Hyun-Mi Kang; Fu-Shi Quan; Richard W Compans; Sang-Moo Kang
Journal:  Mol Ther       Date:  2014-03-04       Impact factor: 11.454

3.  Synthesis and Immunogenicity Assessment of Elastin-Like Polypeptide-M2e Construct as an Influenza Antigen.

Authors:  Rohan S Ingrole; Wenqian Tao; Jatindra N Tripathy; Harvinder S Gill
Journal:  Nano Life       Date:  2014-06-01

4.  Supplemented vaccination with tandem repeat M2e virus-like particles enhances protection against homologous and heterologous HPAI H5 viruses in chickens.

Authors:  Byung-Min Song; Hyun-Mi Kang; Eun-Kyoung Lee; Suk Chan Jung; Min-Chul Kim; Yu-Na Lee; Sang-Moo Kang; Youn-Jeong Lee
Journal:  Vaccine       Date:  2015-12-12       Impact factor: 3.641

5.  A Novel Vaccination Strategy Mediating the Induction of Lung-Resident Memory CD8 T Cells Confers Heterosubtypic Immunity against Future Pandemic Influenza Virus.

Authors:  Yu-Na Lee; Young-Tae Lee; Min-Chul Kim; Andrew T Gewirtz; Sang-Moo Kang
Journal:  J Immunol       Date:  2016-02-10       Impact factor: 5.422

6.  Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity.

Authors:  Min-Chul Kim; Yu-Na Lee; Hye Suk Hwang; Young-Tae Lee; Eun-Ju Ko; Yu-Jin Jung; Min Kyoung Cho; Yu-Jin Kim; Jong Seok Lee; Suk-Hoon Ha; Sang-Moo Kang
Journal:  Vaccine       Date:  2014-08-27       Impact factor: 3.641

7.  A Novel Mechanism Underlying Antiviral Activity of an Influenza Virus M2-Specific Antibody.

Authors:  Rashid Manzoor; Nao Eguchi; Reiko Yoshida; Hiroichi Ozaki; Tatsunari Kondoh; Kosuke Okuya; Hiroko Miyamoto; Ayato Takada
Journal:  J Virol       Date:  2020-12-09       Impact factor: 5.103

8.  Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.

Authors:  Yu-Na Lee; Min-Chul Kim; Young-Tae Lee; Yu-Jin Kim; Jongsang Lee; Cheol Kim; Suk-Hoon Ha; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2015-08-04       Impact factor: 5.970

9.  Immunogenicity and efficacy of replication-competent recombinant influenza virus carrying multimeric M2 extracellular domains in a chimeric hemagglutinin conjugate.

Authors:  Min-Chul Kim; Yu-Na Lee; Yu-Jin Kim; Hyo-Jick Choi; Ki-Hye Kim; Youn-Jeong Lee; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2017-10-26       Impact factor: 5.970

Review 10.  Universal influenza vaccines: from viruses to nanoparticles.

Authors:  Ye Wang; Lei Deng; Sang-Moo Kang; Bao-Zhong Wang
Journal:  Expert Rev Vaccines       Date:  2018-11-02       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.